Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes

FRANEK, E.; HALUZIK, M.; VARZIC, S.; Sargin, MEHMET; MACURA, S.; ZACHO, J.; Christiansen, J.

doi:10.1111/dme.12982

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes

Atıf İçin Kopyala

FRANEK E., HALUZIK M., VARZIC S. C. , Sargin M. , MACURA S., ZACHO J., et al.

DIABETIC MEDICINE, cilt.33, ss.497-505, 2016 (SCI İndekslerine Giren Dergi)

Cilt numarası: 33 Konu: 4
Basım Tarihi: 2016
Doi Numarası: 10.1111/dme.12982
Dergi Adı: DIABETIC MEDICINE
Sayfa Sayısı: ss.497-505

Özet

AimTo evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naive to insulin.